Status:

RECRUITING

PeRsonalized Blood prEssure Management on Postoperative Complications and Mortality in hIgh-risk Patients Undergoing Major Non-cardiac Surgery

Lead Sponsor:

Nanfang Hospital, Southern Medical University

Conditions:

Hypotension

Eligibility:

All Genders

65-90 years

Phase:

NA

Brief Summary

High-risk populations, particularly elderly individuals and patients with cardiovascular comorbidities, exhibit markedly elevated incidences of postoperative myocardial injury (MINS), acute kidney inj...

Detailed Description

Anesthesia- and surgery-related complications and mortality constitute a critical global public health burden. Annually, over 300 million surgical procedures are performed worldwide, with postoperativ...

Eligibility Criteria

Inclusion

  • Aged 65-90 yr;
  • Scheduled to undergo elective non-cardiac major surgery under general anesthesia (with an estimated surgery duration of ≥ 2 hours and an anticipated postoperative hospital stay of ≥ 2 days);
  • Patients with high cardiovascular risk, meeting at least one of the following conditions:
  • History of stroke;
  • History of coronary artery disease;
  • History of congestive heart failure;
  • History of peripheral arterial disease;
  • Preoperative brain natriuretic peptide (BNP) ≥ 92 mg/L or N-terminal pro-brain natriuretic peptide (NT-proBNP) ≥ 300 ng/L;
  • Preoperative cardiac troponin (cTn) or high-sensitivity cardiac troponin (hs-cTn) \> upper reference limit;
  • Hypertension requiring medication treatment;
  • Diabetes requiring medication treatment;
  • History of chronic kidney disease;
  • Continuous smoking for 2 years or more, with interruptions of less than one month before the current hospital admission;
  • Hypercholesterolemia;
  • History of transient ischemic attack.

Exclusion

  • Refuse to participate this trial;
  • Inability to communicate in the preoperative period because of coma, profound dementia, or language barrier;
  • Severe uncontrolled hypertension before surgery (systolic blood pressure ≥ 180 mmHg, diastolic blood pressure ≥ 110 mmHg);
  • Severe hepatic dysfunction (Child-Pugh Class C); or severe renal dysfunction required preoperative dialysis; or American Society of Anesthesiologists (ASA) physical status ≥ V; or expectation lifespan ≤ 24h;
  • Unstable cardiovascular conditions: acute coronary syndrome, decompensated heart failure, severe arrhythmias, severe valvular heart disease;
  • Scheduled to undergo neurosurgical procedures, transplantation, vascular surgery;
  • Urgent surgery;
  • Diagnosed with sepsis or sepsis shock before surgery.
  • Requiring vasopressor treatment before surgery.
  • Unable to finish 24-hour automated blood pressure monitor;
  • Current participation in another interventional study.
  • Any condition deemed ineligible for participation by clinicians.

Key Trial Info

Start Date :

June 3 2025

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 1 2028

Estimated Enrollment :

1624 Patients enrolled

Trial Details

Trial ID

NCT06952387

Start Date

June 3 2025

End Date

December 1 2028

Last Update

July 14 2025

Active Locations (7)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 2 (7 locations)

1

Guangzhou First People's Hospital

Guangzhou, Guangdong, China, 510180

2

Nanfang Hospital, Southern Medical University

Guangzhou, Guangdong, China, 510515

3

The Affiliated Panyu Central Hospital of Guangzhou Medical University

Guangzhou, Guangdong, China, 511431

4

The Third People's Hospital of Shenzhen

Shenzhen, Guangdong, China, 518112